Tysabri - new option for multiple sclerosis

Biogen Idec has launched Tysabri (natalizumab) as single disease modifying therapy in highly active relapsing-remitting multiple sclerosis for patients with high disease activity, despite treatment with interferon beta. It is also licensed for the treatment of patients with rapidly evolving severe relapsing-remitting multiple sclerosis.

PHARMACOLOGY
Natalizumab is a monoclonal antibody thought to act by inhibiting the migration of leukocytes into the central nervous system leading to a reduction of inflammation and demyelination.

CLINICAL STUDIES
The efficacy of natalizumab monotherapy was assessed in a two-year study1 involving 942 patients with relapsing multiple sclerosis who had experienced at least one clinical relapse in the previous 12 months and scored between 0 and 5 on the Kurtzke Expanded Disability Status Scale (EDSS).

Patients received treatment by intravenous infusion every four weeks for more than two years; 627 patients were randomly assigned to the natalizumab group (300mg) and 315 to the placebo group. The study evaluated the rate of clinical relapse at one and two years and the rate of sustained progression of disability, using EDSS, at two years.

After two years of treatment there was a relative risk reduction in the rate of relapse of 68 per cent for patients treated with natalizumab compared to placebo. The risk of sustained disability progression (for 24 weeks) was reduced by 54 per cent in patients treated with natalizumab compared to placebo.2 Natalizumab also showed significant effects on secondary end points, including a 92 per cent reduction in gadolinium enhancing lesions.1

Overall adverse events were similar between the placebo and treatment groups. However, fatigue and allergic reactions were significantly more common with natalizumab compared to placebo.

1. Polman C, Paul M, O'Connor W et al. A randomised, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEJM 2006: Vol 354(9); 899–910.
2. Tysabri Summary of Product Characteristics. Biogen Idec Nov 2007.

Further information: Biogen Idec 01628 501000

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more